TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28586771

Group type: EXPERIMENTAL
Intervention: In-bag manual morcellation (experimental group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Uncontained power morcellation (control group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (in-bag manual morcellation and uncontained power morcellation)
Number of subjects: 72
Study: 27524909

Group type: EXPERIMENTAL
Intervention: Clove-based herbal mouthwash
Number of subjects: 14
Study: 24172719

Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cola matched for caffeine and CHO (CC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Flavored placebo (PL)
Number of subjects: 11
Study: 22233243

Group type: EXPERIMENTAL
Intervention: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 59
Study: 19446864

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg with 400 mg phytosterols
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-enteric coated aspirin 81 mg
Number of subjects: 0
Study: 18382886

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: ACE inhibitor therapy
Number of subjects: 50
Study: 15704148

Group type: EXPERIMENTAL
Intervention: Expressive journal writing
Number of subjects: 43
Study: 12906958

Group type: EXPERIMENTAL
Intervention: Acupressure bands
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Acustimulation band
Number of subjects: 739

Group type: COMPARATOR
Intervention: No band control condition
Number of subjects: 739
Study: 10338176

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 60 mg lidocaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 105
Study: 8609071

Group type: EXPERIMENTAL
Intervention: Pre-operative transcatheter arterial embolization (TAE)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No pre-operative transcatheter arterial embolization (TAE)
Number of subjects: 97
Study: 1938514

Group type: EXPERIMENTAL
Intervention: Low-dose total body irradiation (TBI)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Combination chemotherapy (CHVmP)
Number of subjects: 93
Study: 6110090

Group type: EXPERIMENTAL
Intervention: 2400 rad craniospinal radiation therapy (RT)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: 2400 rad cranial RT plus intrathecal methotrexate (i.t. MTX)
Number of subjects: 478

Group type: COMPARATOR
Intervention: 1800 rad craniospinal radiation therapy (RT)
Number of subjects: 478

Group type: COMPARATOR
Intervention: 1800 rad cranial RT plus intrathecal methotrexate (i.t. MTX)
Number of subjects: 478
Study: 31523425

Group type: EXPERIMENTAL
Intervention: Protein-rich ready-made meals and dairy products
Number of subjects: 98

Group type: COMPARATOR
Intervention: Lower protein products
Number of subjects: 98
Study: 29089169

Group type: COMPARATOR
Intervention: naproxen + placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: naproxen + orphenadrine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: naproxen + methocarbamol
Number of subjects: 240

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: orphenadrine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: methocarbamol
Number of subjects: 240
Study: 26930603

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study: 24997137

Group type: EXPERIMENTAL
Intervention: CbEOb (carboplatin/etoposide with obatoclax)
Number of subjects: 155

Group type: COMPARATOR
Intervention: CbE (carboplatin/etoposide without obatoclax)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: CbEOb
Number of subjects: 155

Group type: COMPARATOR
Intervention: CbE
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: CbEOb and CbE
Number of subjects: 155
Study: 23161047

Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.005% (LP)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No intervention (normals)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No intervention (patients with OH)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No intervention (patients with POAG)
Number of subjects: 199
Study: 20736443

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 17802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study: 18842999

Group type: EXPERIMENTAL
Intervention: Red clover-derived isoflavones (84 mg/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16093744

Group type: EXPERIMENTAL
Intervention: Positive childhood abuse history (women)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Positive childhood abuse history (both genders)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No childhood abuse history (women)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No childhood abuse history (both genders)
Number of subjects: 110
Study: 12613016

Group type: EXPERIMENTAL
Intervention: TAP-144-SR (3M)
Number of subjects: 103

Group type: COMPARATOR
Intervention: TAP-144-SR (1M)
Number of subjects: 103
Study: 11134564

Group type: EXPERIMENTAL
Intervention: Lower-dose platelet transfusions (38% reduction in mean platelet dose)
Number of subjects: 0
Study: 9094889

Group type: EXPERIMENTAL
Intervention: 60%‐carbohydrate diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: 40%‐carbohydrate diet
Number of subjects: 10
Study: 1488937

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (.75 ml/kg)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (.33 ml/kg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control conditions (uncontrollable aversive noise)
Number of subjects: 130
Study: 3099267

Group type: EXPERIMENTAL
Intervention: Intraglobulin (Biotest Pharma, West Germany), 120 mg/kg intravenously, within 2 to 4 hours of delivery (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intraglobulin (Biotest Pharma, West Germany), 120 mg/kg intravenously, on days 1 and 8 (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group received no immunoglobulin (Group C)
Number of subjects: 150
Study: 29341077

Group type: EXPERIMENTAL
Intervention: ESU model with enhanced user interface design principles
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard ESU model
Number of subjects: 36
Study: 27150393

Group type: EXPERIMENTAL
Intervention: 20% glucose intravenous infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline intravenous infusion (control)
Number of subjects: 10
Study: 25663170

Group type: EXPERIMENTAL
Intervention: L-Dopa carbidopa 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pramipexole 1.5 mg (150 mg LED)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23921089

Group type: EXPERIMENTAL
Intervention: Absorbable staples
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metallic staples
Number of subjects: 100
Study: 21619921

Group type: EXPERIMENTAL
Intervention: KRG-body (3g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: KRG-rootlets (3g)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17960793

Group type: EXPERIMENTAL
Intervention: High-dose calcitriol (DN-101; 45 mug) plus docetaxel (36 mg/m2)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo plus docetaxel (36 mg/m2)
Number of subjects: 250
Study: 16504428

Group type: EXPERIMENTAL
Intervention: Oral continuous combined hormone therapy (conjugated equine oestrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d or 5 mg/d)
Number of subjects: 1778
Study: 14583107

Group type: EXPERIMENTAL
Intervention: Standard advanced cardiac life support (ACLS) intervention and empiric early administration of bicarbonate
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Unfavorable outcome risk for men
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Hypertension (HTN) prevalence
Number of subjects: 874
Study: 10892762

Group type: EXPERIMENTAL
Intervention: GAD65 T-cell response in SMS patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: GAD65 T-cell response in T1DM patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GAD65 fragment response in SMS patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: GAD65 fragment response in T1DM patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GAD antibodies in SMS patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: GAD antibodies in T1DM patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: IgG1 isotype in SMS and T1DM patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Other isotypes in SMS patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Other isotypes in T1DM patients
Number of subjects: 31
Study: 8751522

Group type: COMPARATOR
Intervention: High-dose aprotinin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Low-dose aprotinin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 115
Study: 1396839

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches (mean necessary effective patch dose: 125 cm2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) capsules (administered q5h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo patches and capsules
Number of subjects: 8
Study: 30561539

Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine (30 or 100 µg formulated in CAF01 or 100 µg formulated in Alhydrogel)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control vaccine (Verorab)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GMZ2-Alhydrogel (100 µg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 30 µg GMZ2-CAF01
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 µg GMZ2-CAF01
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All groups (GMZ2 and control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline vaccine-specific antibody concentrations
Number of subjects: 50
Study: 28892513

Group type: EXPERIMENTAL
Intervention: Placebo group (told that the odorant increases creativity)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (smelled and rated an odorant)
Number of subjects: 90
Study: 25763862

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg and 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Golimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 23571117

Group type: EXPERIMENTAL
Intervention: Feedback group (real-time feedback)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No-feedback group
Number of subjects: 69
Study: 21717876

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy with Polidocanol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Liquid sclerotherapy with Polidocanol
Number of subjects: 50
Study: 20858034

Group type: EXPERIMENTAL
Intervention: Lidocaine gel combined with ketamine (100 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine gel combined with normal saline
Number of subjects: 60
Study: 17472414

Group type: EXPERIMENTAL
Intervention: Maribavir (100mg bid)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Maribavir (400mg qd)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Maribavir (400mg bid)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 15053030

Group type: EXPERIMENTAL
Intervention: 12-week cognitive-behavioral group intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Individual therapy on request (comparison condition)
Number of subjects: 235
Study: 12195844

Group type: EXPERIMENTAL
Intervention: Nebulised fluticasone propionate (FP) 2 x 0.5 mg/2 ml bd
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral prednisolone 2 mg/kg/day for 4 days followed by 1 mg/kg/day for 3 days (maximum 40 mg then 20 mg)
Number of subjects: 31
Study: 9696374

Group type: EXPERIMENTAL
Intervention: Intrathecal mafosfamide at a dose of 20 mg once or twice weekly until remission, followed by weekly administrations for consolidation and every 3 to 4 weeks for maintenance
Number of subjects: 16
Study: 8596759

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) 10 or 20 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2520814

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg, twice daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Naproxen-sodium (500 mg, twice daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Both flurbiprofen and naproxen-sodium
Number of subjects: 57
Study: 1155823

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Ephedrine
Number of subjects: 16
Study: 30786072

Group type: EXPERIMENTAL
Intervention: NC40 +PHY
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: NC65 +PHY+CA
Number of subjects: 504

Group type: COMPARATOR
Intervention: NC40
Number of subjects: 504

Group type: COMPARATOR
Intervention: NC65
Number of subjects: 504

Group type: COMPARATOR
Intervention: NC40 and NC65
Number of subjects: 504
Study: 28132704

Group type: EXPERIMENTAL
Intervention: MI-only
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MI+HC
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 27129908

Group type: EXPERIMENTAL
Intervention: Anterior-inferior tibiofibular ligament (AITFL) anatomical repair with augmentation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Trans-syndesmosis screw fixation
Number of subjects: 53
Study: 24419415

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 225

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 225
Study: 22812499

Group type: EXPERIMENTAL
Intervention: ICE-guided ablation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Fluoroscopy-only group
Number of subjects: 102
Study: 19275982

Group type: EXPERIMENTAL
Intervention: MoodGYM program in a school-based setting (1000 students, completed over five weeks)
Number of subjects: 8207

Group type: COMPARATOR
Intervention: MoodGYM program in an open access community setting (7207 adolescents)
Number of subjects: 8207
Study: 17967111

Group type: EXPERIMENTAL
Intervention: Communication-centered life skills program implemented over 15 to 20 weeks
Number of subjects: 1581

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1581
Study: 15165599

Group type: EXPERIMENTAL
Intervention: Medial glide taping
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo taping (no glide)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No tape (control)
Number of subjects: 30
Study: 11474002

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a
Number of subjects: 177

Group type: COMPARATOR
Intervention: standard interferon alpha-2a
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: virologic nonresponders (both treatments)
Number of subjects: 177
Study: 9710889

Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor-α monoclonal antibody therapy
Number of subjects: 0
Study: 7822588

Group type: EXPERIMENTAL
Intervention: Conditional Association Task (CAT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Self-Ordered Pointing (SOP) Task
Number of subjects: 72

Group type: COMPARATOR
Intervention: High provocation condition (electric shocks received)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low provocation condition (electric shocks received)
Number of subjects: 72
Study: 2839433

Group type: EXPERIMENTAL
Intervention: Telephone follow-up patient education program
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no telephone follow-up education)
Number of subjects: 51
Study: 31251368

Group type: EXPERIMENTAL
Intervention: Exposure to gun violence in video games
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28063515

Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (3 g/d of fish oil containing 37% eicosapentaenoic acid and 23% docosahexaenoic acid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (3 g/d of sunflower oil containing 65% linoleic acid)
Number of subjects: 80
Study: 25933399

Group type: EXPERIMENTAL
Intervention: Soft contact lens wearers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonwearers
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 23967126

Group type: EXPERIMENTAL
Intervention: trivalent inactivated influenza vaccine
Number of subjects: 340

Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 340
Study: 21324143

Group type: EXPERIMENTAL
Intervention: Sacrospinous fixation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 104
Study: 19118379

Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg twice daily
Number of subjects: 0
Study: 17393330

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum + fructo-oligosaccharides (FOS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16099893

Group type: EXPERIMENTAL
Intervention: 10 weeks of training with acute exercise bouts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-glycogen acute exercise trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal-glycogen acute exercise trial
Number of subjects: 0
Study: 12362670

Group type: EXPERIMENTAL
Intervention: Ultrasound at 0.5 W/cm2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound at 1 W/cm2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional methods (Control)
Number of subjects: 0
Study: 9988796

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 g/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7477617

Group type: EXPERIMENTAL
Intervention: Anti-HCV-positive patients treated on separate machines
Number of subjects: 289

Group type: COMPARATOR
Intervention: Anti-HCV-positive and anti-HCV-negative patients shared the same machines
Number of subjects: 289
Study: 2248817

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine at 19 degrees C
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine at 37 degrees C (sitting position)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine at 37 degrees C (lateral horizontal position)
Number of subjects: 45
Study: 6168363

Group type: EXPERIMENTAL
Intervention: Bleomycin-radiotherapy protocol (15 mg bleomycin I.V. on alternate days followed by radiation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bleomycin-radiotherapy protocol
Number of subjects: 25
Study: 31758887

Group type: EXPERIMENTAL
Intervention: INSURE technique
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MIST technique
Number of subjects: 14
Study: 27501352

Group type: EXPERIMENTAL
Intervention: Eculizumab for 6 months followed by 6 months of observation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: C1q status modeling
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 15
Study: 26625549

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation for 12 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 82
Study: 23490458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study: 21904964

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting a blood glucose level between 4.4 and 6.1 mmol/l (n = 125)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Conventional insulin therapy targeting a blood glucose level less than 11.0 mmol/l (n = 123)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 248
Study: 19556554

Group type: EXPERIMENTAL
Intervention: Hospitalists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teaching teams
Number of subjects: 0
Study: 17436172

Group type: EXPERIMENTAL
Intervention: C-Leg
Number of subjects: 0
Study: 14712285

Group type: EXPERIMENTAL
Intervention: Horse antithymocyte globulin 15 mg/kg/day for 5 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin 3.75 mg/kg/day for 5 days
Number of subjects: 35
Study: 11704367

Group type: EXPERIMENTAL
Intervention: Carotid Angioplasty and Stenting (CAS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 104
Study: 9446334

Group type: EXPERIMENTAL
Intervention: Combined treatment (chemotherapy and radiotherapy) for advanced rectal cancer (T3N1M0 or T4N2M1) and localized large bowel cancer (G2 and G3 grading)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 800
Study: 8426205

Group type: EXPERIMENTAL
Intervention: Cranial irradiation (group A, 31 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No cranial irradiation (group B, 25 patients)
Number of subjects: 100
Study: 3445125

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50 Gy in 20 fractions to the kidney bed, ipsi‐ and contralateral lymph nodes)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Stage II tumours
Number of subjects: 65

Group type: COMPARATOR
Intervention: Postoperative radiotherapy vs observation
Number of subjects: 65